Marshall Wace LLP Has $1.82 Million Position in Accolade, Inc. (NASDAQ:ACCD)

Marshall Wace LLP grew its holdings in Accolade, Inc. (NASDAQ:ACCD) by 2,233.6% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 531,885 shares of the company’s stock after buying an additional 509,093 shares during the quarter. Marshall Wace LLP’s holdings in Accolade were worth $1,819,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in ACCD. Nisa Investment Advisors LLC increased its position in Accolade by 15,113.1% in the 4th quarter. Nisa Investment Advisors LLC now owns 55,680 shares of the company’s stock valued at $190,000 after acquiring an additional 55,314 shares in the last quarter. Barclays PLC grew its stake in shares of Accolade by 164.4% during the third quarter. Barclays PLC now owns 139,901 shares of the company’s stock valued at $539,000 after purchasing an additional 86,981 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Accolade by 4.9% in the third quarter. Geode Capital Management LLC now owns 1,782,038 shares of the company’s stock valued at $6,862,000 after purchasing an additional 83,556 shares in the last quarter. Raymond James Financial Inc. bought a new position in Accolade in the 4th quarter worth approximately $120,000. Finally, Savant Capital LLC lifted its holdings in Accolade by 182.1% during the 4th quarter. Savant Capital LLC now owns 52,794 shares of the company’s stock worth $181,000 after buying an additional 34,082 shares in the last quarter. 84.99% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ACCD has been the subject of a number of recent research reports. William Blair downgraded Accolade from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 8th. Stifel Nicolaus restated a “hold” rating and set a $7.03 target price (down from $8.00) on shares of Accolade in a research report on Thursday, January 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of Accolade in a research note on Wednesday, January 8th. Leerink Partners reissued a “market perform” rating on shares of Accolade in a research note on Wednesday, January 8th. Finally, Canaccord Genuity Group reaffirmed a “hold” rating on shares of Accolade in a research note on Wednesday, January 8th. Thirteen research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Accolade presently has a consensus rating of “Hold” and an average price target of $6.51.

Accolade Price Performance

Shares of ACCD stock opened at $7.02 on Monday. The company has a quick ratio of 2.63, a current ratio of 2.63 and a debt-to-equity ratio of 0.67. Accolade, Inc. has a 12-month low of $3.08 and a 12-month high of $8.36. The firm has a fifty day moving average of $6.99 and a 200-day moving average of $5.43. The firm has a market capitalization of $575.59 million, a price-to-earnings ratio of -3.12 and a beta of 2.10.

About Accolade

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.